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Duringthelastdecade, sporadiccombinationofmultiplesclerosis(MS)andmyastheniagravis(MG)hasbeenreported repeatedly.
Although these are anecdotal, they are important enough to raise concerns about co-occurrence of MG and MS. Here, we present
a case of an MS patient who developed an MG crisis. She had received interferon for relapsing remitting MS. Interestingly, she
developed an MG crisis 4 years after the diagnosis of MS. MS and MG have relatively the same distribution for age, corresponding
to the younger peak of the bimodal age distribution in MG. They also share some HLA typing characteristics. Furthermore,
some evidences support the role of systemic immune dysregulation due to a genetic susceptibility that is common to these two
diseases. The associationmay be underdiagnosed because of the possible overlap of symptoms especially bulbar manifestationsin
which either MG or MS can mimic each other, leading to underestimating incidence of the combination. The evidence warrants
physicians, especially neurologists, to always consider the possibility of the other disease when encountering any patients either
withMSorMG.Anecdotal andsporadicreports ofcombinationofmultiplesclerosis(MS)andmyastheniagravis(MG)havebeen
raised concerns about co-occurrence of them.
1.CaseReport
A 44-year-old woman with deﬁnite MS according to Mc-
Donald criteria and a past history of hypothyroidism was
followed by interferon beta-1b two times per week. Forty-
three months after ﬁrst MS attack, she presented with
regurgitation and dysphagia that appeared 2 months ago.
This was initially considered to be a new attack of MS. By
history taking and neurological examination, other signs
were recognized: easy fatigability (on examination), nasal
speech, and ptosis. The new signs made the neurologist
suspect myasthenia gravis (MG).
The diagnosis of MG was supported by positive edro-
phonium test. Slow repetitive nerve stimulation of spinal
accessory nerve at 3Hz shows a 23% decrement in CMAP
amplitude. This amount of decrement is abnormal and
is consistent with a neuromuscular junction transmis-
sion disorder, but serum acetylcholine receptor antibodies
(ACh-R Ab) were negative. Other antibodies which may be
present in MG patients were not assessed. Computerized
tomography scan of the thorax revealed no thymic enlarge-
mentandjustpersistentremnantsoftheglandweredetected.
She has received 60mg pyridostigmine bromide three times
per day and interferon beta-1b was discontinued. The signs
and symptoms of MG were incompletely relieved after a few
days.
She was discharged with mild orofacial weakness and
followed. After two weeks, she presented with severe bilateral
ptosis, intermittent double vision, chocking during swallow-
ing, and dyspnea. With diagnosis of MG crisis, the patient
was admitted to intensive care unit and underwent tracheal
intubation followed by plasmapheresis 4 sessions comprising
exchange with albumin 2 liters in each day. In addition,
prednisolone25mgperdaywasprescribed.Afterextubation,
pyridostigmine bromide every 4 hours was administered via
nasogastric tube. After plasmapheresis the patient still had2 Case Reports in Medicine
diplopia and ptosis and mild dyspnea and the gag reﬂex was
impaired. The patient had a weight of 60Kg, as a result 120g
(2g/kg)intravenousimmunoglobulinwasadministered over
6 days and produced a dramatic improvement in her clinical
condition. After day 8, the patient showed improvement,
and, after day 14, the patient was discharged with only mild
ptosis and some limitation in vertical eye movement. After
6 months, she neither developed a new attack of MS nor an
MG crisis.
2.Discussion
Interestingly, we described for the ﬁrst time crisis of MG just
twomonthsafter presentationofMGsymptoms. Inprevious
years, coexistence of MS and MG was reported rarely [1].
Supporting evidence comes from an increased incidence
of reported CNS demyelinating disease including MS in
patients with MG [2]. Gotkine et al., in 2006, reported ﬁve
of 214 reviewed patients with MG (2.3%) who had CNS
demyelinating disease. However,only 1patientdeﬁnitelyhad
dissemination in time and space and another possibly such
as neither had typical MS. In the report by Gotkine et al.,
CNS demyelinating disease always occurred subsequent to
the initiation of MG treatment, supporting the possibility
that immunemodulating therapies including thymectomy
and immunosuppression may have a role [3]. It has been
suggested that immune dysregulation could be induced by
thymectomy, and a considerable number of patients showed
diﬀerent autoantibodies in their serum years after thymec-
tomy when compared with nonthymectomized patients and
healthy ones [4]. It has been reported that the clinical
course of both MG and MS is mild in most patients with
this combination of neuroimmunological disorders, but the
onset of MG couldcause an exacerbation ofMS whereas MG
can be relatively unaﬀected by ﬂuctuations in the clinical
course of MS [1, 5]. However, we encountered a case of
MS who developed MG crisis. Consequently, it seems any
clinical course could be expected by these two autoimmune
diseases. In the largest study in Vancouver British Colombia
on patients with well-documented diagnoses of both MS
and MG, 8 patients with co-occurring MS and MG were
reported. The value was signiﬁcantly higher than predicted
by prevalence estimates. MS occurred before MG in six
patients, after MG in seven patients, and within one year
in two patients. According to an epidemiological survey, 15
patients have been reported in the literature with deﬁnite
diagnoses of both MS and MG [1]. In a case series on
1718 patients with deﬁnite MS in Isfahan, Iran, ﬁve MG
were detected (291/100,000; 0.29%) [6]. None of the six
patients was positive for ACh-R Abs. Our case also was
negative for acetylcholine receptor antibodies, but other
series reported more positive results. As a limitation of our
study, evaluation of other antibodies such as antimuscle-
speciﬁc tyrosine kinase antibody, antistriational muscle
antibodies, Titin, antiryanodine receptor antibodies, which
are related to MG was not feasible in our setting. Occurrence
ofthese antibodies couldprovide more documentsregarding
underlying mechanisms that are involved in combination of
MG and MS. However, seronegative results for mentioned
antibodies could not rule out diagnosis of MG and their
assessment is not mandatory.
In addition, three Brazilian patients were reported with
MG that presented distinct demyelinating diseases including
two monophasic and one recurrent neuromyelitis optica, 6–
18 years after the diagnosis of MG. In consistence to the
previous reports, ocular and bulbar manifestation of MG
were the most common ﬁndings in our case [5, 6].
Some rational mechanisms have been hypothesized for
this phenomenon. First, it is a random ﬁnding that could
happen by chance alone. Moreover, it has been considered
as a coincidence of two autoimmune disorder [5]o rM G
may be triggered by interferon treatment via deviation of
immune response towards apredominantly Th2 reaction [7].
It is worth to note that interferon β, apparently, may cause
signs and symptoms of MG by itself, as has been reported
in the literature [7, 8]. However, there are some reports in
which MS occurred after development of MG [5].
Furthermore, two diseases have relatively same distribu-
tionforage,theyoungerpeakofthebimodalagedistribution
in MG and HLA typing (A1, A2, DR3, B8) [9]. Antinuclear
antibodies (ANAs) usually occur in approximately 20 to
30% of MS and 40% of MG patients. The high frequency
of ANAs in MS and MG can support the role of systemic
immune dysregulation [10]. Both of them are related with
some autoimmune disorder. It has been suggested that there
may be some genetic susceptibility that is common to this
group of diseases [11]. It is of note that our patient was
suﬀering from hypothyroidism which, in most cases, mainly
in females, is due to Hashimoto’s disease, another immune
disorder. On the other hand, dysfunction of thyroid gland
may inﬂuence the functional state of the neuromuscular
transmission.
An accidental coincidence of two diseases was excluded
by high signiﬁcant estimation of British Colombia study
as largest series in this setting. Also, the incidence of
demyelinating diseases in patients with MG is much higher
than expected in the general population [7].
Also, presentation of MS subsequent to MG is an argu-
ment against the triggering eﬀect of interferon generating
MG as sole etiology. Furthermore, there were some patients
who developed MG during the course of MS without
treatment with interferon. So, it is too simplistic to pay no
heed to important combination between MS and MG. The
association may be underdiagnosed because of the possible
overlap of symptoms specially cranial manifestations in
which eitherMGorMS canmimic eachothermanifestations
leading to underestimating incidence of new ones. The
evidence warrants physicians, especially neurologists, to
always consider the possible occurrence of the other disease
when encountering a patient with either MS or MG. This
critical question should always be considered: whether the
new symptom could be the ﬁrst presentation of another
disease or not.
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